<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04886453</url>
  </required_header>
  <id_info>
    <org_study_id>BOUHEMAD PHRCI 2019</org_study_id>
    <nct_id>NCT04886453</nct_id>
  </id_info>
  <brief_title>Evaluation of Non-opioid Balanced General Anesthesia in Cardiac Surgery With Extracorporeal Circulation: a Randomized, Controlled, Multicenter Superiority Trial</brief_title>
  <acronym>OFACAR</acronym>
  <official_title>Evaluation of Non-opioid Balanced General Anesthesia in Cardiac Surgery With Extracorporeal Circulation: a Randomized, Controlled, Multicenter Superiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Opioid-free anesthesia (OFA) is a general anesthesia based on the use of hypnotics and&#xD;
      non-opioid analgesics (lidocaine, ketamine, dexamethasone, esmolol). This technique has been&#xD;
      used for the past 10 years, during which randomized and non-randomized studies have&#xD;
      demonstrated a number of positive effects on cardiac function:&#xD;
&#xD;
        -  better analgesia and decreased postoperative morphine consumption,&#xD;
&#xD;
        -  better respiratory function,&#xD;
&#xD;
        -  better hemodynamic stability,&#xD;
&#xD;
        -  better postoperative cognitive function.&#xD;
&#xD;
      The hypothesis of the present study is that the use of OFA during cardiac surgery is&#xD;
      associated with:&#xD;
&#xD;
        -  Improved intraoperative hemodynamic stability&#xD;
&#xD;
        -  A decrease in the incidence of postoperative complications&#xD;
&#xD;
        -  A reduction in intensive care and hospital length of stay&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of at least one postoperative complication</measure>
    <time_frame>30 days post-surgery</time_frame>
    <description>Post-operative complications:&#xD;
postoperative neurological dysfunction&#xD;
acute renal failure&#xD;
acute respiratory failure&#xD;
cardiovascular complications&#xD;
death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Opioid-free Anesthesia</condition>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Balanced general anesthesia without morphine</intervention_name>
    <description>Balanced general anesthesia without morphine</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard general anesthesia balanced with morphine</intervention_name>
    <description>Standard general anesthesia balanced with morphine</description>
    <arm_group_label>Controle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Data collection</description>
    <arm_group_label>Controle</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of pain</intervention_name>
    <description>visual analog scale</description>
    <arm_group_label>Controle</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Recovery quality score</intervention_name>
    <description>QoR15 questionnaire</description>
    <arm_group_label>Controle</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who has provided written and informed consent&#xD;
&#xD;
          -  Adult patient&#xD;
&#xD;
          -  Patient undergoing cardiac surgery which is:&#xD;
&#xD;
               1. Scheduled&#xD;
&#xD;
               2. With bypass surgery&#xD;
&#xD;
               3. Of the following types: aortic valve surgery, mitral valve surgery, tricuspid&#xD;
                  valve surgery, atrial myxoma, coronary artery bypass surgery, aortic surgery,&#xD;
                  combined surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person not affiliated to national health insurance&#xD;
&#xD;
          -  Person under legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Person under court order&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Adult unable to express consent&#xD;
&#xD;
          -  Patient already included once in the study&#xD;
&#xD;
          -  Patient requiring emergency surgery&#xD;
&#xD;
          -  Patients with hypersensitivity to local anesthetics or opiates or to any of the&#xD;
             excipients in the products used&#xD;
&#xD;
          -  Patients on antidepressants, neuroleptics&#xD;
&#xD;
          -  Patients with an unprotected atrioventricular conduction disorder&#xD;
&#xD;
          -  Patients with a prolonged QTc (&gt; 450 ms) on preoperative ECG&#xD;
&#xD;
          -  Patient with severe liver failure (PT&lt; 30%)&#xD;
&#xD;
          -  Patient suffering from respiratory failure&#xD;
&#xD;
          -  Patient with uncontrolled epilepsy&#xD;
&#xD;
          -  Patient with preoperative cognitive dysfunction (MMS &lt;24)&#xD;
&#xD;
          -  Patient with intracranial hypertension&#xD;
&#xD;
          -  Patient with chronic kidney failure (dialysis, creatinine &gt; 200 μmol L-1)&#xD;
&#xD;
          -  Patient with porphyria&#xD;
&#xD;
          -  Patients treated with non-selective MAOIs (iproniazid), selective A MAOIs&#xD;
             (moclobemide), selective B MAOIs (selegiline), gabapentin (Neurontin®) or linezolid&#xD;
             (Zyvoxid®)&#xD;
&#xD;
          -  Patients with severe arterial hypotension (systolic BP&lt;90 mmHg)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Belaid BOUHEMAD</last_name>
    <phone>03.80.29.35.28</phone>
    <email>belaid.bouhemad@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belaid BOUHEMAD</last_name>
      <phone>03.80.29.35.28</phone>
      <email>belaid.bouhemad@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

